Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financi...( - 16% Growth in Annual Net Sales Driv...),Health

- 16% Growth in Annual Net Sales Driven by Demand for Branded Products

- Adjusted Diluted EPS of $2.40 from Operations, up 25% from 2007

- Provides 2009 Adjusted EPS Guidance Range of $2.59 - $2.67

CHADDS FORD, Pa., Feb. 27 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today reported double-digit percentage growth in net sales and adjusted diluted earnings per share for the fourth quarter and full year ended December 31, 2008.

Net sales for the three months ended December 31, 2008 increased 14% to $347.3 million compared with $304.6 million in the fourth quarter of 2007. Net income for the three months ended December 31, 2008 was $74.9 million compared with $50.6 million in the comparable 2007 period.

Diluted earnings per share for the three months ended December 31, 2008 were $0.64 compared with $0.38 in the comparable 2007 period. As detailed in the Supplemental Financial Information below, adjusted diluted earnings per share for the three months ended December 31, 2008 increased 37% to $0.71 compared with $0.52 in the same period in 2007.

Full-Year Results

Net sales for the year ended December 31, 2008 were $1.261 billion compared with $1.086 billion for the year ended December 31, 2007, an increase of 16%. Net income for the year ended December 31, 2008 was $261.7 million versus $227.4 million in the comparable 2007 period.

Diluted earnings per share for the year ended December 31, 2008 were $2.12 compared with $1.69 in the comparable 2007 period. As detailed in the Supplemental Financial Information below, adjusted diluted earnings per share for the full year 2008 increased 25% to $2.40 compared with $1.92 in 2007.

Selected Product Review

LIDODERM
'/>"/>